/
Login
Total Market Cap
12,822.8B
P/E (Weighted)Price to Earnings ratio.
20.30
Medyan: 11.98
P/B (Weighted)Price to Book ratio.
5.00
Medyan: 5.00
P/E (Arithmetic)Simple average P/E.
18.19
Avg Lothien ScoreFinancial health score (0-100).
59
Avg DamodaranDamodaran scoring model.
41
Avg PotentialExpected upside potential %.
-0.8%
Avg Dalio ScoreDalio debt cycle score.
78
Distributions
Lothien Distribution
Damodaran Distribution
Upside Potential
Stocks in Sector
| Stock | PriceCurrent trading price. | Market CapTotal market capitalization. | FKPrice to Earnings ratio. | PD/DDPrice to Book ratio. | EV/EBITDAEnterprise Value / EBITDA. | ROICReturn on Invested Capital. | WACCWeighted Average Cost of Capital (WACC). | PUSLAFinancial health score (0-100). | DamodaranValuation score. | Intrinsic ValueFair value via DCF model. | Potential %Expected upside potential %. | Dalio RiskDalio Debt Cycle Score | Debt/EquityDebt to Equity ratio. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NATCOPHARM
|
841.50 | 150.7B | 3.29 | 1.63 | 3.19 | 8.2% | 15.0% | 80 | 46 | 2,067.90 | +104.9% | 87 | 0.08 |
|
ALKEM
|
5,329.50 | 637.2B | 7.38 | 4.61 | 5.27 | 16.7% | 14.2% | 77 | 47 | 7,870.22 | +34.3% | 85 | 0.15 |
|
GLENMARK
|
2,480.00 | 699.9B | 9.73 | 6.66 | 3.59 | 27.0% | 14.4% | 76 | 60 | 3,547.34 | +32.3% | 87 | 0.06 |
|
GRANULES
|
828.50 | 205.3B | 7.75 | 4.04 | 4.16 | 12.8% | 13.9% | 76 | 48 | 1,319.94 | +42.7% | 80 | 0.30 |
|
ABBOTINDIA
|
25,850.00 | 549.3B | 8.50 | 11.51 | 6.87 | 53.1% | 14.4% | 75 | 61 | 28,889.57 | +8.8% | 88 | 0.04 |
|
ZYDUSLIFE
|
1,161.30 | 1,158.4B | 6.42 | 4.31 | 4.53 | 11.5% | 12.8% | 75 | 48 | 1,944.69 | +48.6% | 71 | 0.47 |
|
ERIS
|
1,297.20 | 179.8B | 6.98 | 4.54 | 4.47 | 10.3% | 13.5% | 74 | 44 | 2,055.77 | +42.1% | 65 | 0.60 |
|
EMCURE
|
1,855.30 | 351.9B | 8.70 | 7.10 | 4.80 | 17.3% | 14.1% | 70 | 46 | 2,422.52 | +22.0% | 67 | 0.31 |
|
IPCALAB
|
1,974.90 | 501.0B | 9.56 | 6.21 | 5.51 | 17.1% | 14.3% | 69 | 43 | 2,387.24 | +15.0% | 86 | 0.10 |
|
AJANTPHARM
|
3,601.90 | 450.1B | 9.91 | 9.94 | 7.13 | 25.4% | 14.4% | 68 | 50 | 3,674.30 | +1.4% | 87 | 0.06 |
|
GLAND
|
2,885.80 | 476.1B | 10.54 | 4.59 | 6.47 | 13.5% | 14.4% | 67 | 42 | 3,350.42 | +11.6% | 87 | 0.03 |
|
MANKIND
|
2,419.20 | 999.1B | 12.23 | 6.13 | 6.69 | 10.7% | 13.0% | 63 | 38 | 2,447.38 | +0.8% | 72 | 0.39 |
|
NH
|
1,907.20 | 389.8B | 11.86 | 8.59 | 5.97 | 20.3% | 14.4% | 61 | 45 | 1,923.00 | +0.6% | 73 | — |
|
GLAXO
|
3,050.10 | 516.7B | 12.09 | 22.79 | 9.20 | 42.2% | 14.4% | 60 | 53 | 2,393.15 | -16.1% | 89 | 0.01 |
|
ONESOURCE
|
1,519.10 | 174.2B | — | 2.99 | 13.70 | 0.6% | 13.8% | 52 | 32 | 1,666.91 | +5.4% | 63 | 0.26 |
|
MEDANTA
|
1,479.70 | 397.8B | 17.88 | 10.04 | 10.29 | 13.6% | 14.2% | 50 | 37 | 979.18 | -25.4% | 83 | 0.30 |
|
PPLPHARMA
|
214.40 | 285.4B | — | 3.49 | 9.16 | 0.9% | 13.1% | 50 | 38 | 239.09 | +6.5% | 61 | 0.70 |
|
ACUTAAS
|
3,160.60 | 258.8B | 16.75 | 15.65 | 11.82 | 25.8% | 14.4% | 49 | 44 | 1,944.88 | -28.8% | 89 | 0.02 |
|
ANTHEM
|
893.05 | 503.2B | 21.84 | 16.54 | 15.32 | 22.7% | 14.4% | 48 | 38 | 442.88 | -37.8% | 89 | 0.02 |
|
ASTRAZEN
|
6,951.50 | 173.8B | 25.61 | 19.91 | 18.88 | 33.6% | 14.4% | 48 | 48 | 2,940.43 | -43.3% | 84 | 0.13 |
|
WOCKPHARMA
|
1,883.70 | 306.1B | 18.71 | 6.19 | 10.75 | 5.6% | 13.9% | 47 | 29 | 1,346.23 | -21.4% | 68 | 0.45 |
|
LAURUSLABS
|
1,915.00 | 1,034.7B | 23.66 | 19.51 | 12.97 | 15.0% | 13.3% | 43 | 32 | 940.67 | -38.2% | 66 | 0.47 |
|
LENSKART
|
662.40 | 1,152.1B | 43.95 | 13.22 | 22.02 | 8.2% | 13.2% | 41 | 24 | 233.96 | -48.5% | 81 | 0.36 |
|
ASTERDM
|
756.00 | 659.0B | 51.70 | 8.51 | 17.20 | 6.0% | 14.2% | 40 | 23 | 311.51 | -44.1% | 79 | 0.29 |
|
NEULANDLAB
|
23,010.00 | 295.2B | 100.00 | 15.75 | 139.22 | 23.7% | 14.3% | 38 | 34 | 6,272.22 | -54.6% | 82 | 0.16 |
|
KIMS
|
755.50 | 317.3B | 38.83 | 14.12 | 11.81 | 5.8% | 13.5% | 36 | 26 | 335.96 | -40.0% | 50 | 1.89 |